MMP inhibitors: Experimental and clinical studies

D. Belotti, P. Paganoni, R. Giavazzi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Matrix metalloproteases (MMPs) are a family of structurally related enzymes that are capable of degrading proteins of the extracellular matrix. These enzymes play a role in tissue remodelling associated with both physiological and pathogenic processes. A high expression of MMPs is associated with cancer malignancy: it is related to the tumor's ability to metastasize and to the process of angiogenesis. Treatment with MMP inhibitors alone or in combination with cytotoxic therapy is an interesting novel approach to control tumor progression. The expected mechanism of action of these compounds and the difference in side effects compared to cytotoxic drugs make the definition of endpoints and the assessment of response difficult. Furthermore, it is not yet clear whether tumor vascularization or, more specifically, MMP expression/activation should be a criterion of eligibility for this kind of treatment. This review provides an overview of the characteristics of MMPs and their role in tumor progression, metastasis and angiogenesis. Preclinical and clinical studies with synthetic MMP inhibitors are described. The presence of MMPs in biological fluids of patients and their use in prognostic evaluation and in determining the efficacy of treatment with MMP inhibitors is discussed.

Original languageEnglish
Pages (from-to)232-238
Number of pages7
JournalInternational Journal of Biological Markers
Volume14
Issue number4
Publication statusPublished - Oct 1999

Fingerprint

Metalloproteases
Tumors
Neoplasms
Physiological Phenomena
Aptitude
Clinical Studies
Extracellular Matrix Proteins
Enzymes
Therapeutics
Chemical activation
Tissue
Neoplasm Metastasis
Fluids
Pharmaceutical Preparations

Keywords

  • Markers
  • Metalloproteases
  • MMP inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

MMP inhibitors : Experimental and clinical studies. / Belotti, D.; Paganoni, P.; Giavazzi, R.

In: International Journal of Biological Markers, Vol. 14, No. 4, 10.1999, p. 232-238.

Research output: Contribution to journalArticle

@article{6d9fdeaa6df0461c86fda33c4a15f91b,
title = "MMP inhibitors: Experimental and clinical studies",
abstract = "Matrix metalloproteases (MMPs) are a family of structurally related enzymes that are capable of degrading proteins of the extracellular matrix. These enzymes play a role in tissue remodelling associated with both physiological and pathogenic processes. A high expression of MMPs is associated with cancer malignancy: it is related to the tumor's ability to metastasize and to the process of angiogenesis. Treatment with MMP inhibitors alone or in combination with cytotoxic therapy is an interesting novel approach to control tumor progression. The expected mechanism of action of these compounds and the difference in side effects compared to cytotoxic drugs make the definition of endpoints and the assessment of response difficult. Furthermore, it is not yet clear whether tumor vascularization or, more specifically, MMP expression/activation should be a criterion of eligibility for this kind of treatment. This review provides an overview of the characteristics of MMPs and their role in tumor progression, metastasis and angiogenesis. Preclinical and clinical studies with synthetic MMP inhibitors are described. The presence of MMPs in biological fluids of patients and their use in prognostic evaluation and in determining the efficacy of treatment with MMP inhibitors is discussed.",
keywords = "Markers, Metalloproteases, MMP inhibitors",
author = "D. Belotti and P. Paganoni and R. Giavazzi",
year = "1999",
month = "10",
language = "English",
volume = "14",
pages = "232--238",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - MMP inhibitors

T2 - Experimental and clinical studies

AU - Belotti, D.

AU - Paganoni, P.

AU - Giavazzi, R.

PY - 1999/10

Y1 - 1999/10

N2 - Matrix metalloproteases (MMPs) are a family of structurally related enzymes that are capable of degrading proteins of the extracellular matrix. These enzymes play a role in tissue remodelling associated with both physiological and pathogenic processes. A high expression of MMPs is associated with cancer malignancy: it is related to the tumor's ability to metastasize and to the process of angiogenesis. Treatment with MMP inhibitors alone or in combination with cytotoxic therapy is an interesting novel approach to control tumor progression. The expected mechanism of action of these compounds and the difference in side effects compared to cytotoxic drugs make the definition of endpoints and the assessment of response difficult. Furthermore, it is not yet clear whether tumor vascularization or, more specifically, MMP expression/activation should be a criterion of eligibility for this kind of treatment. This review provides an overview of the characteristics of MMPs and their role in tumor progression, metastasis and angiogenesis. Preclinical and clinical studies with synthetic MMP inhibitors are described. The presence of MMPs in biological fluids of patients and their use in prognostic evaluation and in determining the efficacy of treatment with MMP inhibitors is discussed.

AB - Matrix metalloproteases (MMPs) are a family of structurally related enzymes that are capable of degrading proteins of the extracellular matrix. These enzymes play a role in tissue remodelling associated with both physiological and pathogenic processes. A high expression of MMPs is associated with cancer malignancy: it is related to the tumor's ability to metastasize and to the process of angiogenesis. Treatment with MMP inhibitors alone or in combination with cytotoxic therapy is an interesting novel approach to control tumor progression. The expected mechanism of action of these compounds and the difference in side effects compared to cytotoxic drugs make the definition of endpoints and the assessment of response difficult. Furthermore, it is not yet clear whether tumor vascularization or, more specifically, MMP expression/activation should be a criterion of eligibility for this kind of treatment. This review provides an overview of the characteristics of MMPs and their role in tumor progression, metastasis and angiogenesis. Preclinical and clinical studies with synthetic MMP inhibitors are described. The presence of MMPs in biological fluids of patients and their use in prognostic evaluation and in determining the efficacy of treatment with MMP inhibitors is discussed.

KW - Markers

KW - Metalloproteases

KW - MMP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0033388462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033388462&partnerID=8YFLogxK

M3 - Article

C2 - 10669951

AN - SCOPUS:0033388462

VL - 14

SP - 232

EP - 238

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -